[Fibrinolysis in pregnancy toxemia].
Pathogenesis of toxemia of pregnancy has been studied of late in terms of coagulation and fibrinolysis, and the results show evidence of hypercoagulability but not of fibrinolysis which has remained unclarified. Our study aims to elucidate the fibrinolytic kinetics of toxemia in normal pregnant women divided into mild and severe types and eclampsia, and also to study changes in the coagulation and fibrinolytic system in toxemia given urokinase. In the affected group the following 1)--3) parameters characteristics were more significant than in other groups. 1) Decreased platelet count. 2) Prolonged ELT. 3) Increased AT-III. 4) There was no significant difference between the groups examined in PT, APTT, Fbg., serum FDP, alpha 2-antipl., alpha 1-AT, alpha 2-MG, C1-INA, and plg. 5) Signs in eclampsia, with region slightly distributed, tended to resemble those in the serious group. 6) alpha 2-antipl., and alpha 1-AT in the case given urokinase tended to decrease. 7) There was observed a case of accelerating and lowering fibrinolysis that appeared simultaneously with the following signs: decreased alpha 2-antipl., increased serum FDP, and prolonged ELT; and also the case whose signs widely changed even after a relatively small dose of urokinase. The results obtained suggest the possibility of variable fibrinolytic kinetics.
D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D011225:Pre-Eclampsia / Q000097:blood* / Q000188:drug therapy; D011247:Pregnancy; D011263:Pregnancy Trimester, Third; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use; D000515:alpha 1-Antitrypsin / Q000032:analysis
D000515:alpha 1-Antitrypsin; D014568:Urokinase-Type Plasminogen Activator